Physician profile
Shantan Ravula
NPI 1245465541
$4,103.14
in general payments reported to CMS, 2019-2025
30 companies · $402 in 2025
The $402 reported for 2025 was less than what a typical Sleep Medicine (Family Medicine) provider received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $1,134 · 2021: $503 · 2022: $342 · 2023: $499 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511 · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.03 |
| Education | $389.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $619.01 | 2019-2025 | |
| Inspire Medical Systems, INC. | $461.31 | 2022-2025 | Inspire |
| Pfizer INC. | $407.28 | 2019-2021 | |
| Novo Nordisk INC | $387.98 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.33 | 2019-2021 | |
| Lilly USA, LLC | $187.14 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.75 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $179.48 | 2019-2020 | |
| Harmony Biosciences LLC | $152.23 | 2020-2025 | Wakix |
| Allergan, INC. | $143.92 | 2020 | |
| Amgen INC. | $137.41 | 2019-2020 | |
| Amarin Pharma, INC. | $135.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $109.79 | 2019-2021 | |
| Abbvie INC. | $103.78 | 2021-2022 | |
| Glaxosmithkline, LLC. | $101.33 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $79.55 | 2022 | |
| Itamar Medical INC | $63.34 | 2022 | |
| Merck Sharp & Dohme LLC | $62.92 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $62.90 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.26 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $33.73 | 2019 | |
| Neos Therapeutics, LP | $29.06 | 2019 | |
| Avanir Pharmaceuticals, INC. | $19.16 | 2019 | |
| Ironshore Pharmaceuticals INC. | $18.46 | 2019 | |
| Eisai INC. | $17.47 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.41 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.31 | 2021 | |
| Antares Pharma, INC. | $14.40 | 2020 | |
| Shire North American Group INC | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shantan Ravula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.